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Brownadipose tissue (BAT) thermogenesis increaseswhenuncouplingprotein-1 (UCP1) is activated
adrenergically and requires T3. In humans, UCP1 activation in BAT seems involved in body weight
maintenance.BAT type2deiodinase (D2) increases in response toadrenergic agents, producing the
T3 required for UCP1 expression. T3 actions are mediated by thyroid hormone nuclear T3 receptors
(TR), TR and TR. Studies in mice suggest that TR is required for UCP1 induction, whereas TR
regulates body temperature and adrenergic sensitivity. In the present study, we compare the
effects of T3 vs. specific TR1 and TR1 agonists [GC-1 and CO23] on the adrenergic induction of
UCP1 and D2 in cultured rat brown adipocytes. T3 and GC-1 produced similar increases on UCP1,
whereas CO23 increased UCP1 only at high doses (50 nM). GC-1 at low doses (0.2–10 nM) was less
potent than T3, increasing the adrenergic stimulation of D2 activity and mRNA. At higher doses,
GC-1 further stimulated whereas T3 inhibited D2 activity but not D2 mRNA, suggesting posttran-
scriptional effects. CO23 had no effect on D2 activity but increased D2mRNA. T3, GC-1, or CO23 by
themselves did not increase UCP1 or D2mRNA. High T3 doses shortened D2 half-life and increased
D2 turnover via proteasome, whereas GC-1 did not change D2 stability. The 1- and 2-adrenergic
D2 responses increased using high T3 doses. In summary, T3 increases the adrenergic stimulation
of UCP1 and D2 expression mostly via the TR1 isoform, and in brown adipocytes, D2 is protected
from degradation by the action of T3 on TR1. (Endocrinology 151: 5074–5083, 2010)
The brown adipose tissue (BAT) is the main site of ad-aptative thermogenesis, providing extraheat in hiber-
nating animals, newborns, and cold-exposed mammals
(cold-induced thermogenesis). Adaptative thermogenesis
provides heat by uncoupling the oxidative phosphoryla-
tion, a function accomplished by the uncoupling protein-1
(UCP1) present in the inner mitochondrial membrane of
brown adipocytes (1). BAT is also important in the main-
tenance of energy balance, because it is activated in re-
sponse to diet (diet-induced thermogenesis) (2). Recent
data showed that BAT is present in humans, and its ac-
tivity correlates inversely with the percentage of body fat
(3–5). BAT thermogenesis is activated in response to nor-
epinephrine (NE), and the adrenergic stimulation induces
UCP1 synthesis. The stimulation is -adrenergic, acting
through the 1- and 3-adrenergic receptors, although
with a participation of 1-adrenergic pathways (6, 7).
Thyroid hormones play a key role in obligatory and
adaptative thermogenesis. Hypothyroid rats are intoler-
ant to cold and die when exposed to cold after several
hours (8), due to a deficient basal and facultative thermo-
genesis. This deficiency is restored by replacement with
thyroid hormones. It has been shown that thyroid hor-
monesarenecessary for the full expressionofUCP1 in vivo
(8, 9). Moreover, T3 amplifies the adrenergic stimulation
of UCP1mRNA expression in cold-exposed rats (10, 11).
T3 also has a direct effect on UCP1 transcription and on
the stabilizationofUCP1mRNAinbrownadipocytes (12,
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13). Several regions of the rat UCP1 promoter have thy-
roid hormone response elements (14). There is a high cor-
relation between the occupancy of nuclear T3 receptors
(TRs) and increases in UCP1 expression (15).
During cold exposure, the type 2 deiodinase (D2) lo-
cally producesT3,whichbinds to andactivates the nuclear
TRs. T3 is required for a full thermogenic function (16,
17), for the adrenergic induction of UCP1, and for lipo-
genesis (18). T3 is also required for the differentiation of
adipocytes (19). D2 is a selenoenzyme that generates T3,
via 5 deiodination of T4 in several organs, including
brain, pituitary, BAT, skin, placenta, and human heart,
muscle, and thyroid. In BAT, D2 (and the production of
T3) is activated by adrenergic stimulation and cold expo-
sure, and a synergism between 1- and -adrenergic path-
ways has been described (20). In cultured brown adipo-
cytes, the presence of T3 is required for the adrenergic
stimulation of D2 (21).
T3 acts through its nuclearTRs, ligand-dependent tran-
scription factors, encoded by two genes: TR and TR
(22). Most actions of T3 are mediated by one of these TR
isoforms, which are expressed at different levels in differ-
ent tissues (23). TR1 is predominant in liver and TR1
in heart. TR1 regulates body temperature and gene ex-
pression in heart. TR1 is essential for TSH regulation,
cochlear development, and hepatic cholesterol metabo-
lism (24, 25). Both TR isoforms are present in adipose
tissue, butTR ismore abundant thanTRß.TR1,TR1,
and c-erbA-2 mRNAs are present in rat brown adipo-
cytes in primary culture (26), in which exposure to T3
increased TRß1 and decreased TR1. It is of great impor-
tance to delineate which are the T3 actions mediated
through each isoform, to optimize the therapeutic bene-
fits, and minimize the toxic side effects of thyromimetic
therapeutic agents.
The development of T3 analogs that bind preferentially
to TRß could be a strategy to obtain beneficial T3 effects
on lipids while avoiding undesirable side effects. The T3
analog GC-1 (also called sobetirome or QRX-431) has an
affinity for TR equal to that of T3 and a 10-fold reduced
affinity for TR1, and shows TR1 selective actions (27).
GC-1 lowers serum cholesterol and triglycerides in mice
with equalorgreaterpotency thanT3,without stimulation
of heart rate (28–30). The effect of T3 on UCP1 is medi-
ated by the TR isoform, because GC-1 increased UCP1
levels, but GC-1 produced an impaired NE response as
measured by the lack of cAMP accumulation in isolated
adipocytes from GC-1-treated hypothyroid mice and
failed to maintain BAT and core body temperature (30).
The differential effects of GC-1 vs. T3 on the thermogen-
esis in BATmay be the result of the GC-1 TR selectivity.
Therefore, the TR1 isoform seems required to maintain
the normal adrenergic responsiveness of the brown adi-
pocyte and body temperature, whereas TRmediates T3-
induced UCP1 gene expression.
The aim of the present study is to compare the effect of
T3 and GC-1 (TR selective analog) and CO23 (TR1
selective analog) (31), on the adrenergic stimulation of
UCP1 mRNA and that of D2 activity and mRNA, using
primary cultures of rat brown adipocytes.
Materials and Methods
Primary cultures of brown adipocytes
All the rats were housed under humane conditions, under
veterinary control, according to the European Community
Guidelines and after the approval of the protocol by the Ethics
Committee of our institution. Precursor cellswere obtained from
the interscapular BAT of 3-wk-old rats (Sprague Dawley), using
the method described by Ne´chad et al. (32) with modifications
(21), using collagenase digestion (0.2%) inDMEM 1.5%BSA
at 37 C, and filtration through 250-m pore size silk filters.
Mature cells were allowed to float, and the infranatant was fil-
trated through 25-m pore size silk filters and centrifuged. Pre-
cursor cells were seeded to get 1500–2000 cells/cm2 on d 1 and
grown in DMEM supplemented with 10% newborn calf serum
(NCS), 3 nM insulin, 10 mM HEPES, 50 IU penicillin and 50 g
streptomycin/ml, and 15 M ascorbic acid. Culture media were
changed on d 1 and every 2nd day thereafter. Precursor cells
proliferated actively in these conditions, reached confluence on
days 4th–5th after seeding (40,000–80,000 cells/cm2), andwere
fully differentiated by day 8th into mature brown adipocytes.
Studies were performed during the period of differentiation (8th
culture day) using NCS or hypothyroid serum in the presence of
thyroid hormones or other treatments, as specified.
Both NCS and hypothyroid serum were used for cell culture.
The hypothyroid serum was obtained by depleting NCS of thy-
roid hormones, using the anion exchange resin AG1X8 (Bio-
Rad, Richmond, CA), as described (33). This treatment also de-
pletes serum from some growth factors and other hormones.
Hypothyroid serum contained less than 10% of the original
amount of thyroid hormones, as assessed by RIA (34). In NCS,
concentrations of T4 andT3were 77 and 0.7 nMT3, respectively.
These levelswere decreased to 2.2 nMT4 and0.13nMT3 inHypo
serum (21). These concentrations are before 10% dilution in the
culture medium.
The free T4 and T3 concentrations were measured by ultra-
filtration andRIA in the culturemedium (DMEM 10%NCS):
35 pM T4 and 2.5 pM T3 (0.45 and 4% of the total T4 and T3
concentrations, respectively) (21). We also measured the free T3
concentrations, when using DMEM  10% hypothyroid se-
rumT3.The freeT3 concentrationwas50and170pMT3when
using 1 and 10 nM T3 in 10% hypothyroid serum, respectively.
In these conditions, the cellular T3 concentrations were 2.3 and
9 nM T3 for 1 and 10 nM T3, respectively. Cellular T3 concen-
trationswere 45 nMT3when using 50 nMT3 added to the culture
medium (DMEM  10% hypothyroid serum).
D2 activity
Cells were scraped, collected in buffer A [0.32 M sucrose, 10
mM HEPES, and 10 mM dithiothreitol (DTT) (pH 7.0)], and
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homogenized. D2 activities were determined in homogenates
measuring the release of iodide, as described (35, 36), using as
final concentrations: 2 nM T4 (50.000 cpm [
125I]-T4), 1 M T3,
50 mM DTT, 1 mM 6-n-propyl-2-thiouracil (PTU), 80–100 g
protein in 100 l of total volume (pH 7.0) during 1 h at 37 C. In
these conditions, more than 95% of D2 activity was insensitive
to inhibitionby6-n-propyl-2-thiouracil (PTU). Each cell homog-
enate was tested in triplicate, using two culture flasks per treat-
ment. The protein content was determined by the method of
Lowry (37), after precipitation of the homogenates with trichlo-
roacetic acid to avoid interference of DTT in the colorimetric
reaction (35). Results were express in fmol/hmg protein.
The high specific activity [125I]-T4 used was obtained in our
laboratory (3000 Ci/g) using chloramine T and T3 as sub-
strate (35, 36). Before each assay, [125I]-T4was purified by paper
electrophoresis to separate the contaminating iodide, using am-
monium acetate 0.05 M (pH 6.8). The amount of iodide in the
blanksassaywas routinely less than1%of the total radioactivity.
Preliminary experiments were performed to validate the as-
say: 1) the production of equimolar amounts of iodide and T3,
2) the linear production of iodide using increasing amounts of
protein, and 3) the within-assay coefficient of variation that
was less than 5%.
RNA preparation and analysis of UCP1 and D2 mRNA
Total cellular RNA was extracted using TRI reagent (Sigma,
St Louis, MO) following the manufacturer’s protocol. For
Northern blot analysis, 15 g total RNA was denatured, elec-
trophoresed, and transferred to nylon membranes to be hybrid-
ized with Ucp1 cDNA. A 1200-bp rat Ucp1 cDNA clone (38)
was used as a probe by labeling with [-32P] deoxy-CTP using
random primers (108 cpm/g DNA). Filters were hybridized
andwashed (39). Autoradiogramswere obtained from the filters
and quantified by NIH Image software. The membranes were
routinely dyed usingmethylene blue to visualize the rRNAs, and
the 28S band was used to correct for differences between lanes.
D2mRNAandUcp1mRNAwere alsomeasured byTaqMan
quantitative RT-PCR (qRT-PCR), using specific TaqMan
gene expression assays from Applied Biosystems (rat Dio2,
Rn00581867-m1; rat Ucp1, Rn00562126-m1; Applied Biosys-
tems, Foster City, CA). Results were normalized using rat ubiq-
uitin as internal control (ratUbc, Rn01789812-g1). For D2 and
Ucp1 expression, results were expressed as fold change vs. con-
trols and were calculated using the 2Ct method. All experi-
ments have been repeated at least two to four times, and the
figures show the mean of two to four experiments.
cAMP analysis
Brownadipocyteswere incubated for 30minwithNEorBRL
37344 in hypothyroid serum supplemented with increasing
doses of T3, GC-1, or CO23 for 24 h. cAMP levels were mea-
sured using the PerkinElmer NEN Life Science Products kit
(PerkinElmer Life Sciences, Boston,MA), according to the man-
ufacturer instructions.
Statistical analysis
Results are expressed asmeans SE.When required, one-way
ANOVA was used. Statistical significance difference between
groups was assessed using the protected least significant differ-
ence test. All the calculationswere done as described in Snedecor
and Cochran (40).
Results
Effects of T3 and GC-1 on the adrenergic
stimulation of UCP1 mRNA
Wehave previously shown that in primary cultures of rat
brown adipocytes, the basal expression of Ucp1 mRNA is
undetectable under standard culture conditions (10%NCS
and insulin), and NE or T3, separately, stimulate poorly
Ucp1mRNA. In rat brown adipocytes, the adrenergic stim-
ulation of Ucp1 requires the presence of NE and T3 (11).
Figure 1A shows the expression of Ucp1, as measured
by Northern blot analysis, stimulated by NE and increas-
ing doses of T3 or GC-1 (0.2–50 nM). Ucp1 mRNA
reached maximal mRNA expression around 2–10 nM T3.
The effect of GC-1 onUcp1mRNAwas similar to that of
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FIG. 1. Effect of T3, GC-1, and CO23 on the adrenergic stimulation of Ucp1 mRNA. Rat brown adipocytes were grown in standard conditions
(10% NCS). Cells were treated during the last 24 h with 1% hypothyroid serum and different doses of T3 and GC-1 (A) or different doses of T3,
GC-1, and CO23 (B). NE (5 M) was added during the last 15 h, and RNA was isolated. A, Ucp1 mRNA expression was measured by Northern blot
analysis, and rRNA was shown to correct for differences between lanes. B, Ucp1 mRNA expression was measured by qRT-PCR, calculated by the
2Ct method, and expressed as fold increases vs. cells treated only with NE (no T3, GC-1, or CO23). Ubiquitin was used as reference gene.
Results are mean  SEM (n  4–6 per point) from three experiments. *, P  0.05 vs. equimolar doses of T3 or GC-1.
5076 Martinez de Mena et al. Effects of GC-1 and T3 on UCP1 and D2 Endocrinology, October 2010, 151(10):5074–5083
T3 in the Northern blot analysis, but the lowest GC-1
concentration seemed to have a lower effect. To check the
results found by Northern blot analysis, we further ana-
lyzed Ucp1 expression by qRT-PCR, using TaqMan
probes and testing theTR1analogCO23 for comparison
(Fig. 1B). T3 andGC-1 both increasedUcp1 expression at
all the doses tested (P  0.05 vs. NE), except at 0.2 nM,
producing a similar dose-dependent effect on Ucp1 (no
difference between equimolar doses of T3 vs. GC-1). The
effect of CO23 was negligible at all except the highest
concentration tested (50 nM; P 0.05 vs.NE alone), and
CO23 had always a lower effect than T3 or GC-1. We
conclude that the effect ofT3on theadrenergic stimulation
of Ucp1 is clearly via the TR1 isoform, as it was repro-
duced using the TR1 agonist, GC-1. Ucp1 was not de-
tectable in the absence of NE. T3, GC-1, or CO23 per se
had no effect (data not shown).
Effects of T3 and GC-1 on the adrenergic
stimulation of D2 activity and mRNA
We have previously shown that the adrenergic stimu-
lation of D2 activity and mRNA requires the presence of
T3 (21, 35). Figure 2 shows the effect of T3, GC-1, and
CO23 on D2 activity (Fig. 2, left) andD2mRNA (Fig. 2,
right). At low doses (2–10 nM), T3 had a higher effect than
GC-1, increasing the adrenergic stimulation of both D2
activity and mRNA, which reached a maximum at 10 nM
T3. At higher doses (10 nM), T3 inhibitedD2 activity but
not D2 mRNA. The high doses of GC-1 (up to 400 nM)
further increasedD2 activity, and an in-
hibition of D2was never observed even
at thehighestGC-1doses tested.Wedid
time-course experiments (from3 to 24 h)
using10and50nMT3and10and100nM
GC-1, to exclude changes in D2 re-
sponses at different times. Before 6 h, 50
nM T3 inhibited D2 activity by only 10–
30%, and 40–50% D2 inhibition was
observedafter6h(from12to24h).GC-1
increased D2 activity linear and steadily
from 3 to 24 h (data not shown). The ef-
fect of GC-1 on D2 mRNA was also
lower than that of T3 up to 10 nM, but at
higher doses, T3 and GC-1 had the same
effect on D2 mRNA. CO23 (0.5–400
nM) had little effect onD2 activity (about
8–15%of 10 nMT3) but had some effect
on D2 mRNA at high doses (10 and 50
nM), about 50% the effect of GC-1. NE,
T3,GC-1,orCO23persedidnot increase
D2 activity. Therefore, the effect ofT3 on
the adrenergic stimulation of D2 pref-
erentially involves TR1 at D2 activity
and mRNA levels. A TR effect onD2mRNA could not
be excluded.
The inhibition by high T3 doses of D2 activity, but not
D2mRNA, suggests posttranscriptional effects at the pro-
tein level (changes in D2 half-life and D2 degradation) or
a possible modulation of the adrenergic pathways. The
inhibition foundusinghighdoses ofT3but not usingGC-1
suggests differences between the actionofT3 throughboth
TR isoforms on the stability of D2 activity.
Effect of high doses of T3 and GC-1 on the
adrenergic pathways for induction of D2 activity
Because we observed different patterns of stimulation
ofD2activity andmRNAwhenusing high doses ofT3 and
GC-1, we tested whether changes in the adrenergic path-
ways were occurring. We have previously shown that the
adrenergic responses of D2 activity and expression occur
via3-adrenergic pathways (21). InFig. 3A,we confirmed
that the adrenergic response of D2 activity is mostly 3-
adrenergic, as shown using the 3 agonist BRL 37344 in
the presence of both T3 andGC-1. The inhibitory effect of
high doses of T3 (50 nM) was observed using both NE and
BRL 37344, though the 3-adrenergic pathway seemed
lower at the high T3 doses (from 75% at 10 nM T3 to 60%
at 50 nM T3), and again, no inhibition was observed using
high GC-1 doses either using NE or BRL 37344.
Wethenanalyzedwhether thedifferencesbetweenT3and
GC-1 could be due to changes in the stimulation of different
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FIG. 2. Effect of T3, GC-1, and CO23 on the adrenergic stimulation of D2 activity and
mRNA. Rat brown adipocytes were grown in standard conditions (10% NCS). Cells were
treated during the last 24 h with 10% hypothyroid serum for D2 activity and 1% hypothyroid
serum for D2 mRNA and different doses of T3, GC-1, or CO23. NE (5 M) was added during
the last 15 h before recollection. Left, Results for D2 activity are expressed taking the 10 nM
T3 dose as 100%. *, P  0.05 vs. 10 nM T3  NE. D2 activities at 10 nM T3 (100%) were
200–400 fmol/hmg protein. Data are means SEM (n 4–10 per dose) from 10 experiments
expressed as percentage of control. The lines indicate the effect of NE alone or “no NE” in the
presence of T3, GC-1, or CO23. Right, D2mRNA was measured using qRT-PCR, calculated by the
2Ct method, and expressed as fold increases vs. cells treated only with NE (no T3 or GC-1 or
CO23). Ubiquitin was used as reference gene. Data are means SEM (n 6) from three
experiments. *, P 0.05 T3 vs. GC-1; #, P 0.05 T3 vs. CO23; &, P 0.05 CO23 vs. basal.
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adrenergic pathways (ß- and -adrenergic pathways). For
this, we used NE and 10 or 50 nM T3 or 50 nMGC-1, in the
presenceof1-,2-,and-adrenergicantagonists (prazosin,
yohimbine, and alprenolol, respectively). Figure 3B shows
that at 10 nM T3, the adrenergic response was mostly -ad-
renergic (60% of control), whereas the 1-adrenergic path-
way was 25% of control (prazosin). Blocking of - and
1-adrenergic receptors, we observed that both adrenergic
pathwayswereadditive,andthe inhibitionofD2activitywas
about 80%. A small 2-adrenergic component (not signifi-
cant) was also detected using yohimbine (10%).
At high doses (50 nM T3), we found differences in the
adrenergic responses of D2 activity; the 1-adrenergic path-
way increased up to 54%, and the 2-adrenergic pathway
increasedup to20%.At50nMGC-1, the resultswere similar
tothatof10nMT3.The-adrenergicpathwaywas72%,and
the 1-adrenergic component was 30% of control, and no
participation of the 2-adrenergic pathway was found. In
summary, high T3 doses change the pattern of adrenergic
responses increasing the -adrenergic pathways.
cAMP levels
We then examined whether the differences found in
the participation of the different adrenergic pathways
using high doses of T3, the lack of stimulation of D2
activity by CO23, and the inhibition of D2 activity at
high doses of T3 could be due to a change in cAMP
production.
Brown adipocytes were incubated with increasing doses
of T3, GC-1, or CO23 for 24 h, NE or BRL 37344 were
added for the last 30min, and the cAMPproducedwasmea-
sured (Table 1). NE or BRL 37344 produced a 7-fold in-
crease in cAMP production (from 0.74 to 5 pmol/ml). T3 or
GC-1 (10 nM and above) further increased cAMP (Table 1);
the largest cAMP increases were found using the 3 agonist
BRL 37344 and 200 nM GC-1.
T3andCO23 induced similar increases in cAMP,which
were lower than using GC-1, indicating that CO23 is as
effective as T3 stimulating cAMP production. We did not
observe inhibition in cAMP production in the presence of
high doses of T3 or using CO23. The levels of cAMP are
higher using BRL 37344, increasing with high T3 and
GC-1 doses.
Mechanisms of degradation of D2 activity with T3
and GC-1
We also investigated whether the half-life and the deg-
radation ofD2 activitywere different in the presence of 10
and 100 nM T3 and 200 nM GC-1.
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FIG. 3. A, Effects of high doses of T3 and GC-1 on the adrenergic induction of D2 activity. Cells were treated for 24 h with increasing doses of T3 (A) or
GC-1 (B) in 10% hypothyroid serum, and NE or BRL 37344 (5 M) were added during the last 15 h. Results for D2 activity are expressed taking 10 nM T3
 NE as 100%. D2 activities at 10 nM T3 NE (100%) were 200–400 fmol/hmg protein. Data are means SEM (n 4–20 per point) from 10
experiments. B, D2 activity. Changes in the adrenergic pathways using 10 or 50 nM T3 and 50 nM GC-1 in brown adipocytes. Cells were treated for 24 h
with 10 or 50 nM T3 or 50 nM GC-1 in 10% hypothyroid serum. NE (5 M) was added during the last 15 h in the presence of different adrenegic
antagonists [for 1, prazosin (P); 2, yohimbine (Y); , alprenolol (A)] at 10 nM, added 1 h before NE. Results for D2 activity are expressed taking 10 nM
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D2 half-life
Brown adipocytes were treated with 10 nM, 100 nMT3,
or 200 nM GC-1 for 24 h, and NE was added for the last
15 h. Then, cycloheximide was added and cells collected
at different times up to 2 h. Figure 4A shows that D2
half-lifewas similarwhenusing 10nMT3or 200nMGC-1,
and both induced a stabilization of D2 activity, but the
half-life in the presence of 100 nM T3 was shorter than
using 10nMT3or 200nMGC-1 (1h), indicating a higher
turnover rate of D2 activity.
D2 degradation
We also tested whether high doses of T3 could be
modulating the degradation of D2 via the proteasome.
Previously, we confirmed the role of proteasome in D2
degradation in our cultures of brown adipocytes (41).
TABLE 1. cAMP levels in response to 5 M NE or BRL37344. Effect of T3, GC-1, and CO23 addition
Doses NE (5 M) T3 GC-1 CO23
4.69  0.32
0.2 nM 7.53  1.75 6.48  0.85d 6.60  0.48
2 nM 5.57  1.11 6.08  0.31d 6.85  0.67
10 nM 9.16  1.81a 11.55  2.18a,b 7.16  0.94a
50 nM 16.15  0.61a,b,c,d 7.64  0.67a
100 nM 6.59  0.11
200 nM 16.35  2.36a,b,c,d
BRL 37344 (5 M)
5.65  0.70
0.2 nM 6.10  0.59d 10.04  1.70
2 nM 7.97  1.86d 12.49  1.58a
10 nM 13.63  2.68a,b 14.04  2.73a
50 nM 15.34  1.96a,c
100 nM 9.65  0.59
200 nM 19.87  1.90a,b,c,d
Cells were incubated for 24 h with several doses of T3, GC-1, and CO23 in 10% hypothyroid serum. NE or BRL37344 (at 5 M) were added for
the last 30 min. Data are expressed as picomoles per ml (means  SEM, n  2–4). Basal levels (without NE) were 0.74  0.13 pmol cAMP/ml.
a P  0.05 vs. NE or BRL 37344.
b P  0.05 vs. its corresponding lower dose (0.2 nM).
c P  0.05 vs. the equimolar T3 dose.
d P  0.05 vs. its corresponding 10 nM dose of T3 or GC-1.
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FIG. 4. A, Half-life of D2 using 10 or 100 nM T3 and 200 nM GC-1. Cells were treated for 24 h with 10 or 100 nM T3 or 200 nM GC-1 in 10%
hypothyroid serum. NE (5 M) was added during the last 15 h. Then, cycloheximide (CHX) (25 M) was added, and cells were harvested at 0, 30, 60, 90,
and 120 min, using controls without CHX at the same times. CHX by itself had no effect. Data are means SEM (n 10–12 per point) from six
experiments. B, Effect of proteasome inhibitor MG132 on D2 activity. Cells were treated for 24 h with 100 nM T3 or 200 nM GC-1 in 10% hypothyroid
serum. NE (5 M) was added during the last 15 h. MG132 (10 M) was added during the last hour of adrenergic stimulation. MG132 by itself had no effect.
Results for D2 activity are expressed taking 100 nM T3NE or 200 nMGC-1NE as 100%. *, P 0.05. Data are means SEM (n 14–18 per point) from
nine experiments.
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Now,we compare the effect of the proteasome inhibitor
MG132 added during the last hour of adrenergic stim-
ulation in cells treated with 100 nM T3 or 200 nM GC-1.
The use of MG132 (Fig. 4B) led to increases in D2 ac-
tivity in 100 nM T3-treated adipocytes (140%), whereas
no differences in D2 activity were found in cells treated
with or without MG132 in the presence of 200 nM
GC-1. This indicates that high doses of T3 increase the
proteasome activity and higher degradation rates of D2
than with GC-1 treatment.
Modulation of TR isoforms by GC-1 and CO23
We also examined whether T3 or the analogs used
(GC-1 and CO23) in the conditions and doses used in the
present study could be modulating the expression of the
TR isoforms (TR and TR). The changes found were
small and did not showed dose-dependent changes (Mar-
tinez de Mena R and Obregon MJ, unpublished results).
The changes do not justify the responses found in UCP1
and D2. The expression of TR was always higher than
that of TR, and the expression of both isoforms was
higher in cultured cells than in BAT tissue, although the
proportion of both TR isoforms (TRTR) is main-
tained in BAT and cells (Martinez de Mena, R. and M. J.
Obregon, unpublished results).
Finally, we have summarized the findings of this study
and from other studies in Fig. 5.
Discussion
T3 has a profound influence in adipose tissue, regulating
the differentiation of the adipocyte, the process of li-
pogenesis and lipolysis, and many genes involved in
lipid metabolism (19). T3 is also involved in the regu-
lation of energy balance by regulating body weight and
basal and adaptative thermogenesis. Research is cur-
rently underway to identify the TR isoform responsible
for each specific action of T3, to enable and facilitate the
development of selective thyromimetic therapeutic
agents. The use of genetically modified mice for TR,
TRß, or both isoforms has shed some light on the spe-
cific physiological functions regulated by each isoform
(42), but due to redundancy of the isoforms, some ef-
fects are not yet clearly identified. Therefore, the use of
specific analogs for TR and TRß may help to identify
FIG. 5. Role of TR and TR isoforms in brown adipocyte thermogenesis. Binding of NE to the -adrenergic receptors activates adenylate cyclase
(AC), increasing cAMP levels. This event activates lipolysis and the expression of cAMP-dependent genes, namely, UCP1, D2, and proteins involved
in adrenergic responses. Intracellular T3 increases through D2 activation, and there is a synergism between T3 and cAMP actions. T3 increases
cAMP, through both TR isoforms. T3, via TR1, increases UCP1 expression and D2 activity and expression, although a TR effect on D2 expression
is also present. High doses of T3 change the pattern of D2 adrenergic stimulation increasing 1-adrenergic pathways. High T3 doses shorten D2
half-life and increase D2 degradation, whereas the TR1 isoform stabilizes D2 activity. CRE, cAMP response element; FFA, free fatty acids; AR,
adrenergic receptors; PLC, phospholipase C; DAG, diacylglycerol; PKC, protein kinase C; PKA, protein kinase A; PIP2, phosphatidylinositol
4,5-bisphophate.
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selective effects of T3mediated predominantly by one of
the TR isoforms (43).
In the present study, we examine the effect of T3 action
onTR1 andTRß1 in the adrenergic stimulation ofUCP1
mRNAandD2activity andmRNA,using specific agonists
of the TR1 and TRß1 isoforms. The T3 effect on both
genes is mediated preferentially via the TRß isoform, al-
though the TR isoform might participate in the regula-
tion of D2 mRNA.
The adrenergic stimulation ofUCP1 is clearlymediated
by the TRß isoform as shown by using GC-1, and GC-1 is
as effective as T3. This agrees with previous work using
injections of GC-1 in hypothyroid mice, describing that
the T3 effect on UCP1 occurs via TRß (30). In that report,
GC-1 restored UCP1 levels in hypothyroid mice, but did
not increase cAMP levels in floating brown adipocytes
from GC-1-treated hypothyroid mice incubated with ad-
renergic agents (30). In contrast to these findings, we find
that GC-1NE increases cAMP levels even better than
T3NE, and no defect is found to increase cAMP produc-
tion in brown adipocytes. It should be considered that the
systemsused in theRibeiro study (30) and the present ones
are different (the species used, hypothyroid-treated mice
vs. control rats, floating vs. cultured adipocytes, etc.),
which could account for the differences found. A recent
report described defective UCP1 levels in TRß PVmutant
mice, indicating the need of the TRß isoform for UCP1
expression (44) and for cAMP production, although no
clear-cut effectswere found inaprevious report usingmice
devoid of all TRs (45).
T3 increases UCP1 transcription but also stabilizes its
mRNA by increasing its half-life (11, 13). Our results in-
dicate that GC-1 possibly acts on both effects of T3 on
UCP1, because the effect of CO23 on UCP1 is very small
and only found at high doses.
We have also examined another key enzyme in BAT,
D2. D2 is the main source of T3 in BAT, especially under
adrenergic stimulation, providing theT3 required for ther-
mogenesis. D2 is frequently used as a marker of thermo-
genesis and for the presence of BAT, because D2 is highly
increased under adrenergic stimulation together with the
up-regulation of UCP1. In rat brown adipocytes, the ad-
renergic stimulationofD2expression requiresT3 (21, 35).
The specific TR isoforms involved in the regulation of D2
activity andmRNAhave not been previously studied.Our
data indicate that TRß is the main pathway for the acti-
vation of the D2 adrenergic stimulation by T3. However,
we find several important differences between the effect of
T3 and GC-1 on D2 and UCP1. First, the TR1 analog
CO23, at high doses, has an effect on D2 mRNA but not
onD2activity. It is possible thatCO23at highdosesmight
be interactingwith TRß, because the functional selectivity
of this compound is about 10-fold (31). Second, the dose-
response curves for GC-1 and T3 are shaped differently:
GC-1 displays a standard sigmoidal curve, whereas the T3
curve is bell shaped, making it difficult to assess the dose
dependence of T3.
Another main difference is the inhibition of D2 activity
by high T3 doses, which was not found using large doses
ofGC-1.We have previously observed a similar inhibition
of D2 activity when using triiodothyroacetic acid (Triac),
a natural thermogenic compound, in brown adipocytes
(46). Triac increased D2 activity at doses lower than T3
with a maximum at 1 nM, and at higher doses, Triac in-
hibited D2 activity. The inhibition found using high T3
doses might be a regulatory pathway down-regulating T3
production by D2, against a T3 excess. In hyperthyroid-
ism, D2 is inhibited (47), and during chronic cold expo-
sure,D2 activity decreases after somedays, indicating that
high T3 concentrations in BAT switch off the mechanisms
of T3 production, via D2. T3 concentrations in BAT are
rather high (5–8 nM) in control rats and after 48-h cold
exposure increase up to 25 nM T3, as measured by RIA in
BAT (48). The T3 concentrations we used for cultures are
rapidly inactivated in culture by D3 (activated by serum),
and after 24 h, we found only 40% of the initially added
T3 (49). Using 10 and 50 nM T3, the T3 concentrations in
our cells are 9 and 45 nM T3, as measured by RIA (see
Materials and Methods). Therefore, using high T3 doses,
the T3 concentration in our cells (45 nM) is double those
found in BAT of cold-exposed rats for 2 d (25 nM), a
physiological condition in BAT.
Because the inhibition observed on D2 activity was not
found at the mRNA level, this suggested posttranscrip-
tional effects of T3 onD2 stability.D2 is inactivated by the
proteasome; rT3 reduces D2 activity by accelerating its
degradation (50). The effect ofMG132on the proteasome
inhibits substrate-induced degradation, and the stabiliza-
tion ofD2 occurs (51). D2 is inactivated by conjugation to
ubiquitin, and the protein deubiquitinating enzyme-1 re-
verses its inactivation prolonging the D2 half-life. Deu-
biquitinating enzyme-1 markedly increases in brown adi-
pocytes by NE and cold exposure (52), suggesting
stabilization of D2 in cold exposure. Ubiquitination is a
regulator of D2 stability, a step critical for its catalytical
activity and dimerization (53). It has not been described
that T3 could regulate the proteasome activity or increase
D2 degradation, as this process was always associated to
degradation by the sustrate, rT3, but it is evident that high
T3 doses increase D2 degradation as shown using the pro-
teasome inhibitor MG132 and measuring D2 half-life.
The TRß1 isoform could be participating in the stabiliza-
tion of D2.
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Another possibility is that T3 induces changes in the
adrenergic pathways used to stimulate D2 activity. In our
culture, the adrenergic stimulation of D2 is mostly ß3-
adrenergic (21), but the first studies on D2 activity in rat
BAT identified the adrenergic response to cold as 1-ad-
renergic (54), because prazosin inhibitedD2 increases and
local T3 production. The changes we observed with high
T3 doses point in the same direction: an increase in the
1-adrenergic pathway. TRß is likely to play a role in
adrenergic signaling at one of the multiple sites under thy-
roid hormone regulation as the regulation of the different
adrenergic pathways (55).
The level of expression of both TR isoforms could be
modulated by the treatments used, especially when using
high doses of T3 or the analogs. But our preliminary studies
on TRs expression does not support the hypothesis of an
induction of the TR and TR isoforms by the treatments
used that could justify the changes found in UCP1 and D2.
Our studies support the view thatTRßagonists, used to
control cholesterol in humans, might be useful tools to
increase energy expenditureand facultative thermogenesis
in humans (27). Other TRß agonists, such as GC-24, in-
creases energy expenditure, eliminating the increased ad-
iposity without causing cardiac hypertrophy and normal-
ized plasma triglycerides, BAT being the main target (56).
A recent report confirms the effect of GC-24 on a battery
of genes inbrownadipocytes butnot inmyocytes, together
with increases in energy expenditure and clear effects on
BMI, and gene expression in control mice, although these
changes were not observed in obese mice on high-fat diet
(57).Metabolic diseases in addition to dyslipemia, such as
obesity, metabolic syndrome, and diabetes, could be
treated safely and effectively by TRß analogs. GC-1 by
increasing UCP1 and D2 activity and its stability could
help to maintain an adequate T3 production in BAT and
to prolong the thermogenic effects of T3, diminished in
obesity, as well as in the low T3 syndrome induced during
caloric restriction and fasting, situations in which ther-
mogenesis is diminished.
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